Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis

References 

1. Mouton JW, Hollander J, Horrevorts AM. Emergence of antibiotic resistance amongst P. aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother. 1993;31:919–926
   • MEDLINE
2. Matz GJ. Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am. 1993;26:705–712
   • MEDLINE
3. Walker PD, Barri Y, Shah SV. Oxidant mechanisms in gentamicin nephrotoxicity. Renal Failure. 1999;21:433–442
   • MEDLINE
   • CrossRef
4. Cheng K, Smyth R, Govan J, et al.  Spread of β-lactam resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348:639–642
   • Abstract
   • Full Text
   • Full-Text PDF (59 KB)
   • CrossRef
5. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, et al.  Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science. 1969;166:122–123
   • MEDLINE
6. Forsgren A, Walder M. Antimicrobial activity of fosfomycin in vitro. J Antimicrob Chemoth. 1983;11:467–471
7. Bergan T. Pharmacokinetic comparison between fosfomycin and other phosphonic acid derivatives. Chemother. 1990;1(36 Suppl):10–18
8. Shimizu K. Fosfomycin: Absorption and excretion. Chemother. 1977;1(23 Suppl):153–158
9. Kirby WM. Pharmacokinetics of fosfomycin. Chemother. 1977;1(23 Suppl):141–151
10. Farago E, Kiss IJ, Nabradi Z. Serum and lung tissue levels of fosfomycin in humans. Int J Clin Pharmacol Ther Toxicol. 1980;18:554–558
    • MEDLINE
11. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann NY Acad Sci. 1974;235:364–386
12. Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother. 1994;34:853–858
    • MEDLINE
13. Morin JP, Olier B, Voitte G, Fillastre JP. Can fosfomycin reduce the nephrotoxicity of aminoglycosides?. Pathol Biol (Paris). 1984;32:338–342
    • MEDLINE
14. Inouye S, Niizato T, Takeda U, Koeda T. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodynam. 1982;5:659–669
15. Ohtani I, Ohtsuki K, Aikawa T, Sato Y, Anzai T, Ouchi J. Mechanism of protective effect of fosfomycin against aminoglycoside ototoxicity. Auris Nasus Larynx. 1984;11:119–124
    • MEDLINE
16. Ohtani I, Ohtsuki K, Aikawa T, Sato Y, Anzai T, Ouchi J, et al. Protective effect of fosfomycin against aminoglycoside ototoxicity. ORL J Otorhinolaryngol Relat Spec. 1985;47:42–48
    • MEDLINE
    • CrossRef
17. Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. 1998. Antimicrobial Sensitivity Guidelines. British Society of Antimicrobial Chemotherapy. Birmingham, UK
18. Anwar H, Strap JL, Costerton JW. Establishment of ageing biofilms: possible mechanisms of bacterial resistance to antimicrobial therapy. Antimicrob Ag Chemother. 1992;36:1347–1351
19. Hoyle BD, Costerton JW. Bacterial resistance to antibiotics: the role of biofilms. Prog Drug Res. 1991;37:91–105
    • MEDLINE
20. Costerton JW, Lam J, Lam K, Chan R. The role of the microcolony mode of growth in the pathogenesis of Pseudomonas aeruginosa infections. Rev Infect Dis. 1983;55(Suppl 5):S867–S873
21. Kumon H, Tomochika K, Matanuga T, Ogawa M, Ohmori H. A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol. 1994;38:615–619
    • MEDLINE
22. Kumon H, Ono N, Iida M, Nickel JC. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Ag and Chemotherapy. 1995;39:1038–1044
23. Figueredo VM, Neu HC. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother. 1988;22:41–50
    • MEDLINE
24. Courcol RJ, Martin GR. In vitro activity of the combination of ceftriaxone and fosfomycin against Staphylococci. J Antimicrob Chemother. 1987;19:276–278
    • MEDLINE
25. Takahashi K, Kanno H. Synergistic activities of combinations of β-lactams, fosfomycin and tobramycin against Pseudomonas aeruginosa. Antimicrob Ag Chemother. 1984;26:789–791
26. Ulmann U, Lindemann B. In vitro investigations on the action of fosfomycin alone and in combination with other antibiotics on Pseudomonas aeruginosa and Serratia marcescens. Arzneimittelforschung. 1980;30:1247–1249
    • MEDLINE
27. Daza R, Moreno-Lopez M, Damaso D. Interactions of fosfomycin with other antibiotics. Chemother. 1977;1(23 Suppl):86–92
28. Tessier F, Quentin C. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1997;16:159–162
    • MEDLINE
    • CrossRef
29. Schulin T. In vitro activity of the aerosolised agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother. 2002;49:403–406
    • MEDLINE
    • CrossRef
30. Woodruff HB, Mata JM, Hernandez S, Mochales S, Rodriguez A, Stapley EO, et al.  Fosfomycin: Laboratory studies. Chemother. 1977;1(23 Suppl):1–22
31. Inouye S, Niizato T, Komiya I, Yuda Y, Yamada Y. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rat. J Pharmacobiodynam. 1982;5:941–950
32. Jardin A. A general practitioner multicentre study: fosfomycin trometamol single dose vs. pipemidic acid multiple dose. Infection. 1990;2(18 Suppl):S89–S93
33. MacGowan AP, Bailey RA, Egner W, Picken DM, Reeves DS. An open study of the efficacy and safety of single dose fosfomycin trometamol in the treatment of hospitalised patients with urinary tract infection (pilot study). Infection. 1990;2(18 Suppl):S107–S108
34. Mayama T, Yokota M, Shimatani I, Ohyagi H. Analysis of oral fosfomycin calcium (Fosmicin) side effects after marketing. Int J Clin Pharmacol Therap Toxicol. 1993;31:77–82
35. Wolter JM, Bowler SD, McCormack JG. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?. Aust NZ J Med. 1999;29:15–21